• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • NORTH AMERICA EDITION
    Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • NORTH AMERICA EDITION
    North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Life Science Market
Life Science News
Life Science Stocks
  • Life Science Market
  • Life Science News
  • Life Science Stocks

Prostate Surgery Best First-Line Treatment for Localized Prostate Cancer, Study Says

Vivien Diniz
Mar. 05, 2014 11:53AM PST
Life Science Investing

A major European study, recently found that men with localized prostate cancer who choose prostate removal surgery have a higher rate of survival than those who opt for radiotherapy

A major European study, recently found that men with localized prostate cancer who choose prostate removal surgery have a higher rate of survival than those who opt for radiotherapy. The 15-year study catologed more than 34,000 Swedish men who underwent the treatment.

According to the company’s press release:

While the highest survival rates were seen among younger patients with non-metastatic prostate cancer, even older men within the more advanced stages of the disease benefited from the surgery-first approach. David B. Samadi, MD, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital, world-renowned prostate cancer expert and inventor of the Samadi Modified Advanced Robotic Technique (SMART) for prostate surgery, emphasized that the study results are consistent with his long held views on the benefits of prostate surgery. “When prostate cancer is diagnosed early, robotic surgery is the best way to optimize prostate cancer recovery and long-term survival.”

Click here to view the full press release. 

 

prostate cancer
The Conversation (0)

Go Deeper

AI Powered

Will Cancer be Cured Under Trump?

FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone

FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone

Latest News

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Emyria Launches Global Services Platform Targeting International Drug Sponsors

Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness

Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

More News

Outlook Reports

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
    • Electric Vehicles
  • Agriculture
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Energy
    • Uranium
    • Oil and Gas
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Robotics
    • Crypto
    • Cleantech
Life Science
    • Biotech
    • Cannabis
    • Pharmaceuticals

Featured Life Science Investing Stocks

More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES